Reviva Pharmaceuticals Holdings, Inc. Common Stock (RVPH) Stock Price

RVPHStock
$0.47−96.00%52W
Market Cap$6.23M
P/E—
PEG Ratio—
Div yield—
Beta0.61

RVPH Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-54.97%
Price vs S&P 500 (4W)-4.57%
VGM Score34.82

RVPH Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.41-$0.19+53.66%(+$0.22)
Q1 2026-$0.29-$0.46-58.62%(-$0.17)
Q4 2025-$1.07-$5.19-386.56%(-$4.12)
Q3 2025-$1.94-$1.20+38.24%(+$0.74)
Q2 2025-$2.20-$2.40-9.09%(-$0.20)

RVPH Analyst Recommendations

Feb 2026
Mar 2026
Apr 2026
May 2026
4.08
4.08
4.00
4.00

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
RVPHReviva Pharmaceuticals Holdings, Inc. Common Stock
——D————$0.47
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Reviva Pharmaceuticals Holdings, Inc. Common Stock

Reviva Pharmaceuticals is a late-stage biopharmaceutical company developing therapeutics for central nervous system, inflammatory, and cardiometabolic diseases. Its lead candidate, Brilaroxazine (RP5063), targets multiple neuropsychiatric indications including schizophrenia, bipolar disorder, depression, ADHD, and dementia-related psychosis, with RP1208 also in development. The company uses a chemical genomics-driven platform and proprietary chemistry to discover and develop new medicines.